Pancreatic Disorders & Therapy
Open Access

Imaging Modalities in the Diagnosis and Monitoring of Pancreatic Diseases

Julian Cortez^{* *}Correspondence: Julian Cortez, Department of Radiology, Greenfield University, Ashton City, Brazil, Email:

Author info »

Description

Pancreatic diseases encompass a range of conditions, including acute and chronic pancreatitis, pancreatic cysts, and pancreatic malignancies. Timely and accurate diagnosis is essential for optimizing treatment strategies and improving outcomes. Imaging techniques play a central role in detecting pancreatic abnormalities, assessing disease severity, guiding interventions, and monitoring progression or response to therapy. Selection of an appropriate imaging modality depends on clinical presentation, suspected pathology, and patient factors such as age, comorbidities, and renal function.

Ultrasound represents a common first-line imaging tool due to its accessibility, non-invasiveness, and cost-effectiveness. Transabdominal ultrasonography can detect pancreatic enlargement, calcifications, fluid collections, and ductal dilation. Its utility is limited in certain scenarios, particularly in obese patients or when intestinal gas obstructs visualization, which can reduce sensitivity. Nonetheless, ultrasound is often employed for initial assessment and follow-up of uncomplicated cases, as well as guiding percutaneous drainage of pancreatic collections.

Computed Tomography (CT) provides detailed cross-sectional images and is frequently used in the evaluation of acute pancreatitis and pancreatic tumors. Contrast-enhanced CT allows for assessment of pancreatic parenchyma, necrosis, vascular involvement, and adjacent structures. In acute pancreatitis, CT can identify necrotic areas, pseudocysts, and complications such as hemorrhage or infection. In malignancy, CT assists in staging by revealing tumor size, local invasion, lymph node involvement, and distant metastases. Multiphase CT protocols enhance vascular visualization, aiding surgical planning and interventional procedures.

Magnetic Resonance Imaging (MRI) offers high-resolution soft tissue contrast without ionizing radiation, making it especially useful for evaluating pancreatic cystic lesions, ductal abnormalities, and chronic pancreatitis. MR CholangioPancreatography (MRCP) is a specialized MRI technique that visualizes the pancreatic and biliary ducts noninvasively. MRCP provides detailed anatomical information, allowing identification of strictures, stones, and congenital anomalies. MRI can also characterize tissue composition, helping differentiate between benign and malignant lesions and supporting treatment decisions.

Endoscopic Ultrasound (EUS) combines endoscopy with highfrequency ultrasound, providing exceptional visualization of the pancreas from within the gastrointestinal tract. EUS is particularly effective for detecting small tumors, evaluating pancreatic masses, and guiding fine-needle aspiration or biopsy. Its high spatial resolution and ability to perform real-time sampling make it a valuable tool in cases where conventional imaging is inconclusive. EUS is also useful for assessing chronic pancreatitis, delineating ductal changes, and detecting early fibrosis.

Positron Emission Tomography (PET), often combined with CT (PET/CT), offers functional imaging that reflects metabolic activity within pancreatic tissue. PET is primarily used in the evaluation of malignancy, identifying areas of high glucose uptake that may correspond to tumor foci. PET/CT can detect recurrent or metastatic disease, complementing structural imaging modalities. While PET is less frequently employed for routine pancreatitis evaluation, it contributes valuable information in complex or uncertain cases.

Each imaging modality has limitations and strengths that must be considered when designing a diagnostic or monitoring plan. CT and MRI provide comprehensive anatomical assessment but involve higher costs and, in the case of CT, exposure to radiation. Ultrasound is non-invasive and repeatable but may miss subtle lesions. EUS allows targeted intervention but requires specialized expertise and sedation. PET adds metabolic information but is less available and more expensive. Effective use of imaging often involves combining techniques to achieve optimal accuracy.

Serial imaging is essential for monitoring disease progression, evaluating response to therapy, and detecting complications. In pancreatitis, repeated imaging can track necrosis resolution, fluid collection evolution, and vascular involvement. In cystic lesions, imaging at defined intervals allows surveillance for changes in size, morphology, or features suggestive of malignancy. In cancer, imaging is critical for post-treatment evaluation, identifying recurrence, and guiding additional interventions.

Advances in imaging technology continue to improve the evaluation of pancreatic disorders. Innovations such as contrastenhanced ultrasound, diffusion-weighted MRI, and highresolution EUS provide more precise information on tissue perfusion, cellular density, and subtle structural changes. These enhancements support earlier detection, more accurate risk stratification, and more effective management strategies.

Conclusion

Imaging modalities are central to the diagnosis, monitoring, and management of pancreatic diseases. Ultrasound, CT, MRI, EUS, and PET each contribute unique information regarding structure, function, and tissue characteristics. Selection and combination of these techniques should be guided by the clinical scenario, suspected pathology, and patient-specific factors. Consistent imaging follow-up ensures timely detection of disease progression or complications, ultimately supporting improved patient outcomes.